J.P. Morgan has downgraded German specialty chemicals manufacturer Evonik Industries AG to a “neutral” rating from “overweight,” while slashing its price target from €20 to €14. This move, announced on November 28, 2025, reflects a weakened earnings outlook through 2027, influenced by persistent structural headwinds and an evolving competitive landscape. The downgrade underscores concerns about Evonik’s profitability pressure and strained dividend coverage in the near term.

Downgrade Reflects Earnings and Structural Challenges

The brokerage revised down Evonik’s profit forecasts amid sustained cyclical and structural issues. Adjusted EBITDA projections were reduced by 6.8% for 2026 to €1.82 billion and by 7.9% for 2027 to €1.98 billion. Corresponding adjusted EPS forecasts declined by 12.6% to €1.18 for 2026 and 11% to €1.44 for 2027. Fourth-quarter 2025 adjusted EBITDA was lowered by 5% to €354 million, positioning it slightly under consensus estimates. Meanwhile, full-year 2025 adjusted EPS was marginally raised by 1.7% to €1.35.

A key factor impacting this downgrade is Evonik’s methionine segment, a commodity animal feed additive contributing roughly 15-17% of the firm’s adjusted EBITDA in 2025. J.P. Morgan highlighted new capacity additions in China, such as Hebang’s planned facility alone equaling nearly 25% of current global output. Such expansions raise the risk of oversupply and intensify pricing pressures starting in 2028, prompting J.P. Morgan to model additional price softness through 2027.

Dividend Reductions and Cost-Savings Delays

Free cash flow is expected to cover only about 70% of Evonik’s 2025-26 dividend payments, driving J.P. Morgan to cut the dividend forecast by 35% to €0.75 per share. Despite this reduction, the dividend yield remains an attractive 6%. The firm also expressed concerns over slow execution of cost-saving measures, with projected net savings of €400 million by 2027—approximately 20% of 2024’s adjusted EBITDA—falling behind initial goals. Wage inflation in Germany, noted as above average, contributes notably to these shortfalls.

J.P. Morgan indicated that if Evonik can exceed €150 million in annual cost savings in 2026-27, there could be positive upside risk to earnings and sentiment.

Market Response and Valuation Perspective

Evonik’s stock performance mirrors these challenges. Shares have dropped 20.7% year-to-date and 23.7% over the last twelve months, underperforming its benchmark index. The stock is trading at a forward price-to-earnings ratio of 9.8 times based on 2025 earnings, below its five- and 10-year median valuations of 12.4x and 13.4x, respectively. The new €14 price target equates to a 5.3x enterprise value/EBITDA multiple for 2027, reflecting an approximately 30% discount to the company’s historical 10-year average.

Despite the downgrade, J.P. Morgan retains Evonik as its preferred stock in the European chemicals sector, emphasizing exposure to Germany, which accounts for about 17% of the group’s revenues and could benefit from potential economic stimulus initiatives.

Downgrade: Market Outlook

J.P. Morgan’s downgrade and revised forecasts highlight fundamental constraints on Evonik’s profitability and cash flow amid expanding global methionine capacity and cost pressures. With earnings trimmed notably through 2027 and the dividend cut by over a third, investors face a cautious outlook. How effectively Evonik manages these structural challenges and accelerates cost savings will be critical in shaping its valuation and market performance going forward. The downgrade signals ongoing investor wariness as the sector balances supply expansions and profitability sustainability.